Evolus Statistics
Total Valuation
Evolus has a market cap or net worth of $450.41 million. The enterprise value is $574.30 million.
| Market Cap | 450.41M |
| Enterprise Value | 574.30M |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolus has 66.19 million shares outstanding. The number of shares has increased by 2.25% in one year.
| Current Share Class | 66.19M |
| Shares Outstanding | 66.19M |
| Shares Change (YoY) | +2.25% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 10.87% |
| Owned by Institutions (%) | 63.85% |
| Float | 49.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 68.05 |
| PS Ratio | 1.38 |
| Forward PS | 1.19 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.42
| Current Ratio | 1.42 |
| Quick Ratio | 0.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.07 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -4.37% |
| Return on Invested Capital (ROIC) | -8.66% |
| Return on Capital Employed (ROCE) | -12.44% |
| Weighted Average Cost of Capital (WACC) | 10.61% |
| Revenue Per Employee | $891,707 |
| Profits Per Employee | -$85,238 |
| Employee Count | 365 |
| Asset Turnover | 1.29 |
| Inventory Turnover | 1.91 |
Taxes
In the past 12 months, Evolus has paid $772,000 in taxes.
| Income Tax | 772,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.07% in the last 52 weeks. The beta is 1.34, so Evolus's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | -0.07% |
| 50-Day Moving Average | 7.81 |
| 200-Day Moving Average | 6.31 |
| Relative Strength Index (RSI) | 38.74 |
| Average Volume (20 Days) | 818,512 |
Short Selling Information
The latest short interest is 6.41 million, so 9.68% of the outstanding shares have been sold short.
| Short Interest | 6.41M |
| Short Previous Month | 5.63M |
| Short % of Shares Out | 9.68% |
| Short % of Float | 12.84% |
| Short Ratio (days to cover) | 8.44 |
Income Statement
In the last 12 months, Evolus had revenue of $325.47 million and -$31.11 million in losses. Loss per share was -$0.47.
| Revenue | 325.47M |
| Gross Profit | 215.00M |
| Operating Income | -17.60M |
| Pretax Income | -30.34M |
| Net Income | -31.11M |
| EBITDA | -8.28M |
| EBIT | -17.60M |
| Loss Per Share | -$0.47 |
Balance Sheet
The company has $41.70 million in cash and $165.59 million in debt, with a net cash position of -$123.89 million or -$1.87 per share.
| Cash & Cash Equivalents | 41.70M |
| Total Debt | 165.59M |
| Net Cash | -123.89M |
| Net Cash Per Share | -$1.87 |
| Equity (Book Value) | -37.81M |
| Book Value Per Share | -0.57 |
| Working Capital | 59.36M |
Cash Flow
In the last 12 months, operating cash flow was -$2.65 million and capital expenditures -$2.26 million, giving a free cash flow of -$4.91 million.
| Operating Cash Flow | -2.65M |
| Capital Expenditures | -2.26M |
| Depreciation & Amortization | 9.32M |
| Net Borrowing | 9.98M |
| Free Cash Flow | -4.91M |
| FCF Per Share | -$0.07 |
Margins
Gross margin is 66.06%, with operating and profit margins of -5.41% and -9.56%.
| Gross Margin | 66.06% |
| Operating Margin | -5.41% |
| Pretax Margin | -9.32% |
| Profit Margin | -9.56% |
| EBITDA Margin | -2.54% |
| EBIT Margin | -5.41% |
| FCF Margin | n/a |
Dividends & Yields
Evolus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.25% |
| Shareholder Yield | -2.25% |
| Earnings Yield | -6.98% |
| FCF Yield | -1.09% |
Analyst Forecast
The average price target for Evolus is $15.40, which is 126.30% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.40 |
| Price Target Difference | 126.30% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 15.76% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolus has an Altman Z-Score of -1.46 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.46 |
| Piotroski F-Score | 2 |